184 related articles for article (PubMed ID: 38114644)
1. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.
Lin TT; Xiong W; Chen GH; He Y; Long L; Gao XF; Zhou JL; Lv WW; Huang YZ
Acta Pharmacol Sin; 2024 Apr; 45(4):867-878. PubMed ID: 38114644
[TBL] [Abstract][Full Text] [Related]
2. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming Tumor-Associated Macrophages To Reverse EGFR
Peng H; Chen B; Huang W; Tang Y; Jiang Y; Zhang W; Huang Y
Nano Lett; 2017 Dec; 17(12):7684-7690. PubMed ID: 29160717
[TBL] [Abstract][Full Text] [Related]
4. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
5. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
6. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F; Ramalingam SS; Owonikoko T; Earp HS; DeRyckere D; Graham DK
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35708914
[TBL] [Abstract][Full Text] [Related]
7. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
8. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR
Yin W; Zhao Y; Kang X; Zhao P; Fu X; Mo X; Wang Y; Huang Y
Theranostics; 2020; 10(14):6122-6135. PubMed ID: 32483443
[TBL] [Abstract][Full Text] [Related]
9. Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.
Sun Y; Dong Y; Liu X; Zhang Y; Bai H; Duan J; Tian Z; Yan X; Wang J; Wang Z
EBioMedicine; 2022 Sep; 83():104200. PubMed ID: 35932642
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.
Fukuda K; Takeuchi S; Arai S; Kita K; Tanimoto A; Nishiyama A; Yano S
Cancer Sci; 2020 Jul; 111(7):2374-2384. PubMed ID: 32391602
[TBL] [Abstract][Full Text] [Related]
11. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
12. Landscape of Acquired Resistance to Osimertinib in
Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
14. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
[TBL] [Abstract][Full Text] [Related]
15. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
Rotow JK; Lee JK; Madison RW; Oxnard GR; Jänne PA; Schrock AB
J Thorac Oncol; 2024 Feb; 19(2):227-239. PubMed ID: 37806383
[TBL] [Abstract][Full Text] [Related]
16. Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun SY
Mol Oncol; 2020 Apr; 14(4):882-895. PubMed ID: 32003107
[TBL] [Abstract][Full Text] [Related]
17. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.
Liang XM; Qin Q; Liu BN; Li XQ; Zeng LL; Wang J; Kong LP; Zhong DS; Sun LL
Acta Pharmacol Sin; 2021 Apr; 42(4):648-654. PubMed ID: 33414509
[TBL] [Abstract][Full Text] [Related]
19. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
20. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]